Literature DB >> 30045910

Gene editing in human development: ethical concerns and practical applications.

Janet Rossant1.   

Abstract

The amazing power of CRISPR-Cas9 gene editing tools and other related technologies has impacted all areas of biology today. It has also raised ethical concerns, particularly with regard to the possibility of generating heritable changes in the human genome - so-called germline gene editing. Although technical and safety issues suggest that this approach is far from clinical application, gene editing as a research tool is moving forward in human embryos, non-human primates and in stem cell-derived embryoids. These studies are already providing new information relevant to our understanding of normal human development, infertility, early pregnancy loss and pluripotent stem cell origins.
© 2018. Published by The Company of Biologists Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 30045910     DOI: 10.1242/dev.150888

Source DB:  PubMed          Journal:  Development        ISSN: 0950-1991            Impact factor:   6.868


  4 in total

Review 1.  Updated perspectives on vascular cell specification and pluripotent stem cell-derived vascular organoids for studying vasculopathies.

Authors:  Chenxin Liu; Kaiyuan Niu; Qingzhong Xiao
Journal:  Cardiovasc Res       Date:  2022-01-07       Impact factor: 10.787

Review 2.  Bioengineered microenvironment to culture early embryos.

Authors:  Zhen Gu; Jia Guo; Hongmei Wang; Yongqiang Wen; Qi Gu
Journal:  Cell Prolif       Date:  2020-01-09       Impact factor: 6.831

3.  Safe-by-Design: Stakeholders' Perceptions and Expectations of How to Deal with Uncertain Risks of Emerging Biotechnologies in the Netherlands.

Authors:  Britte Bouchaut; Lotte Asveld
Journal:  Risk Anal       Date:  2020-05-18       Impact factor: 4.000

Review 4.  Homology-based repair induced by CRISPR-Cas nucleases in mammalian embryo genome editing.

Authors:  Xiya Zhang; Tao Li; Jianping Ou; Junjiu Huang; Puping Liang
Journal:  Protein Cell       Date:  2021-05-04       Impact factor: 14.870

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.